Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer - PubMed
5 hours ago
- #Pancreatic Cancer
- #Non-Small-Cell Lung Cancer
- #KRAS G12D
- Setidegrasib (ASP3082) is a first-in-class KRAS G12D-targeted protein degrader evaluated in a phase 1 study for advanced solid tumors with KRAS p.G12D variants.
- The study involved 203 patients, with 76 receiving the selected phase 2 dose of 600 mg. Adverse events occurred in all patients, with 42% experiencing grade 3 or higher events.
- Common treatment-related adverse events included transient infusion-related reactions (80%) and nausea (30%). Discontinuation due to adverse events was rare (2 patients).
- In NSCLC patients (n=45), 36% had a partial response, median progression-free survival was 8.3 months, and 12-month overall survival was 59%.
- In pancreatic ductal adenocarcinoma patients (n=21), 24% had a response, median progression-free survival was 3.0 months, and median overall survival was 10.3 months.
- Setidegrasib showed antitumor activity with a low discontinuation rate in KRAS p.G12D-mutated NSCLC or pancreatic cancer patients.